A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
The purpose of this study is to initially observe the safety and effectivity of RC18 in
 Participants with Primary Sjögren's Syndrome.
Inclusion Criteria:

 -  Voluntarily signed informed consent ;

 -  Patient with primary Sjögren's syndrome according to the European - American consensus
 group criteria.

 -  Seropositive at screening for anti-Ro/Sjögren's syndrome type A(SSA) antibodies

 -  ESSDAI score ≥ 5.

 Exclusion Criteria:

 -  Diagnosis of secondary Sjogren's syndrome, such as rheumatoid arthritis, systemic
 lupus erythematosus, systemic sclerosis and other autoimmune diseases;

 -  Abnormal laboratory parameters need to be excluded, including but not limited to:

 -  Immunosuppressive agents were used within 4 weeks prior to randomization.;

 -  The use of hydroxychloroquine was allowed during the trial, and the pre-randomized
 drug regimen was stable for less than 12 weeks;

 -  Use of biological agents for targeted therapy in the first 6 months of randomization;

 -  Treatment of primary Sjogren's syndrome with traditional Chinese medicine and
 proprietary Chinese medicine within 4 weeks before randomization;

 -  The use of saliva-stimulating drugs within 7 days prior to randomization;

 -  Sodium hyaluronate eye drops, artificial tears can be used, and the stability time of
 the randomized pre-medication scheme is less than 4 weeks;

 -  Intravenous immunoglobulin therapy or plasma exchange therapy within 6 months before
 randomization;

 -  Infection with herpes zoster or HIV and hepatitis C virus(HCV) antibody positive;

 -  Currently suffering from active hepatitis or severe liver lesions and history;

 -  Malignant tumor patients ;

 -  Combined with involvement of important organs or neuropathy;

 -  Have participated in any clinical trial in the first 28 days of the initial screening
 or 5 times half-life period of the study compound (taking the time for the shorter).

 -  Pregnant , lactating women and men or women who have birth plans during the research;

 -  Investigator considers candidates not appropriating for the study